635713-68-7

Usage

Uses

Used in Pharmaceutical Industry:
2'',3''-DIHYDRO-2''-OXOSPIRO-[PIPERIDINE-4,4''(1H'')-QUINAZOLINE is used as a potential pharmaceutical candidate for the development of new drugs due to its unique structure and the presence of the quinazoline ring, which is known to be a part of several bioactive compounds.
The specific applications and reasons for its use in the pharmaceutical industry would need to be determined through further research and development, as the provided materials do not detail specific uses beyond the potential for pharmaceutical applications. 2'',3''-DIHYDRO-2''-OXOSPIRO-[PIPERIDINE-4,4''(1H'')-QUINAZOLINE's unique properties, including the spiro ring system and the ketone group, may contribute to its efficacy in treating certain conditions or diseases, but these would be subject to validation through scientific studies and clinical trials.

Upstream product

• 64-10-8 phenyl carbamate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 635713-67-6 1-benzyl-2',3'-dihydro-2'-oxospiro-[piperidine-4,4'(1'H)-quinazoline] 

Relevant academic research and scientific papers

Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor

We report the synthesis of rigid spirocyclic systems as conformationally constrained variants of the Ala-Phe-NH2 dipeptide amide C-terminus of the calcitonin gene-related peptide (CGRP). CGRP receptor antagonists containing these moieties displ

CGRP ANTAGONISTS

The present invention relates to novel CGRP antagonists of the general formula (I) in which U, V, X, Y, R1, R2, R3 are defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, and the hydrates of the salts, particularly the physiologically compatible salts thereof having inorganic or organic acids or bases, pharmaceuticals comprising said compounds, the use thereof, and the method for the production thereof.

Novel therapeutic agents for the treatment of migraine

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their u

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.